Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Squamous Cell Carcinoma of Head and Neck 37Nasopharyngeal Carcinoma 27Lung Neoplasms 25Uterine Cervical Neoplasms 22Biliary Tract Neoplasms 22Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 18Head and Neck Neoplasms 17Cholangiocarcinoma 16Urinary Bladder Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Ovarian Neoplasms 13Esophageal Neoplasms 12Carcinoma 12Colorectal Neoplasms 11Stomach Neoplasms 10Small Cell Lung Carcinoma 10Carcinoma, Transitional Cell 8Mouth Neoplasms 7Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Recurrence 6Nasopharyngeal Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Bile Duct Neoplasms 5Peritoneal Neoplasms 4

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Neoplasms × Cisplatin × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡